Director/PDMR Shareholding

RNS Number : 0564K

e-Therapeutics plc

24 July 2013

 

24 July 2013

e-Therapeutics plc ("e-Therapeutics" or the "Company")

Director/PDMR Shareholding

The Company received notification on 20 July 2013 that Novotech Syndicate LLP, an entity in which Professor Malcolm Young (CEO) has an indirect interest, sold 1,230,177 shares in e-Therapeutics plc at 35.5p per share on 15 July 2013. The Company was also notified at the same time that Novotech Investment Limited (NIL), a company of which Professor Young is a director and in which he has options to subscribe for ordinary shares, had sold 50,000 ordinary shares in e-Therapeutics plc at 27p per share on 7 May 2013 and a further 125,059 shares at the same price on 8 May 2013. In all cases, Professor Young had no knowledge of the proposed sales and had no ability by himself to prevent them (as one of three directors in NIL and not being a direct voting member of Novotech Syndicate LLP). It is understood that NIL and Novotech Syndicate LLP have disposed of the shares in order to discharge their obligations to third parties.

Following these sales, Professor Young, who previously had an indirect holding in e-Therapeutics of 374,800 shares, no longer has an indirect holding in the Company. His direct beneficial interest in the Company remains unchanged at 20,644,958 shares, representing 7.83% of the total issued share capital of the Company.

-Ends-

For more information, please contact:

e-Therapeutics plc

Daniel Elger

Tel: [phone]

www.etherapeutics.co.uk 

Panmure Gordon (UK) Limited

Investment Banking: Fred Walsh / Grishma Patel

Corporate Broking: Hannah Woodley

Tel: [phone]

www.panmure.com

 

END

 

 

RDSLLFELDFISFIV